Fidson dominates Nigeria’s Pharma sector first-quarter 2026

Fidson Healthcare has maintained its dominant position in Nigeria's pharmaceutical sector during the first quarter of 2026, according to reports from local media. The company, which operates within a market second only to South Africa in terms of value and among the largest in Africa by population and consumption volume, continues to lead despite ongoing reliance on imported medicines. Nigeria's pharmaceutical market, valued between $2 billion and $3.3 billion, is projected to grow at a compound annual rate of 6.5 percent through 2029. Over-the-counter drugs account for nearly two-thirds of the market, reflecting rising healthcare awareness and urbanization pressures. The Nigerian pharmaceutical landscape remains heavily dependent on imports, with more than 90 percent of active pharmaceutical ingredients and excipients sourced abroad. Despite these challenges, several local manufacturers, including Fidson, May & Baker, and Mecure Industries, have managed to increase their presence in the market. Fidson, in particular, has emerged as a key player, leveraging partnerships with international firms such as Haleon, a British multinational consumer health company known for brands like Sensodyne and Panadol. Fidson's performance in the first quarter of 2026 saw its revenue rise to N42.6 billion, marking a year-on-year increase from N35 billion. This growth comes after a series of strong performances, with the company achieving record revenues of N119.1 billion in fiscal year 2025, a 53.3 percent jump from N84.1 billion. The company's success is attributed to both favorable market conditions and proactive government policies aimed at boosting local drug production. These efforts align with a broader goal of increasing the local share of national drug production to 70 percent by 2030. A significant factor contributing to Fidson's growth has been the expansion of its ethical drug portfolio, which accounted for 56.3 percent of its turnover in the first quarter. Ethical drugs, often used in treating chronic illnesses and other long-term conditions, have become a cornerstone of the company's strategy. In addition, Fidson's exports, though modest at N1.8 billion, representing just 4.3 percent of its total revenue, showed substantial improvement compared to the N146.5 million recorded in the same period the previous year. The company's strategic moves have included forming alliances with global players. In September 2024, Fidson entered into a joint venture with Chinese pharmaceutical firms Jiangsu Aidea Pharma, Nanjing PharmaBlock, and the Beijing-based China-Africa Development Fund. This collaboration underscores the growing importance of cross-border partnerships in the Nigerian pharmaceutical sector. Further reinforcing its market leadership, Fidson has made strides in vaccine development. In April 2026, the National Agency for Food and Drug Administration and Control granted provisional approval for the R21 Malaria Vaccine, paving the way for a partnership with the Serum Institute of India Pvt Limited. This collaboration aims to address clinical malaria in children aged 5 to 36 months and reduce malaria-related deaths in tropical regions of Africa. These developments highlight Fidson's continued commitment to innovation and its role in shaping the future of Nigeria's pharmaceutical industry. As the sector evolves, driven by both domestic initiatives and international collaborations, Fidson remains at the forefront, navigating the complex interplay of local manufacturing constraints and global market trends.